Mazdutide® Injection for Adults

Mazdutide® is a once-weekly injectable medicine under study for obesity and type 2 diabetes. This page explains what is known today and how US shipping from Canada works without insurance. Availability depends on regulatory approvals and supply.

What Mazdutide Is and How It Works

At a high level, this investigational therapy is a dual agonist that engages the GLP-1 receptor and the glucagon receptor. By activating these targets, the treatment may reduce appetite, slow stomach emptying, and help the body use energy more efficiently. These effects can support weight control and help lower blood sugar in adults with type 2 diabetes when paired with diet and activity.

CanadianInsulin is a prescription referral service. We verify your prescription with your clinic, and licensed Canadian pharmacies dispense your order.

This medicine does not have an approved US or Canadian label at this time. If it is authorized in the future, directions for use, warnings, and patient instructions will be defined in the official prescribing information. Any use should follow your prescriber’s guidance and the final label.

Who It’s For

The candidate is being studied for adults with excess weight or obesity and for adults with type 2 diabetes. It may be considered as part of a broader plan for Obesity care and Type 2 Diabetes management, alongside nutrition, physical activity, and ongoing monitoring. It can also fit into structured Weight Management programs when clinically appropriate.

People with a personal or family history of medullary thyroid carcinoma or MEN 2 should not use GLP-1 receptor–based therapies. Those with a history of pancreatitis, severe gastrointestinal disease, or serious allergic reactions to similar medicines may also need different options. Discuss pregnancy and breastfeeding with your clinician before starting any new treatment.

Dosage and Usage

In clinical studies, the therapy is given as a subcutaneous injection once weekly on the same day each week. Injections are placed into the abdomen, thigh, or upper arm, rotating sites to reduce local irritation. It can be taken with or without food. Do not share injection devices or reuse needles.

Do not mix this medicine with other injectables in the same syringe. Follow your clinician’s instructions for starting dose and any adjustments. Because there is no approved label yet, exact directions may differ if the product is authorized in the future. When uncertain, defer to the official label and your prescriber’s guidance.

Strengths and Forms

Study materials have included single-use or multi-use presentation formats such as prefilled pens or vials. Investigational strengths explored in trials include 2 mg, 3 mg, 4 mg, and 6 mg given once weekly. Final marketed presentations and strengths, if approved, may differ, and availability can vary by pharmacy and jurisdiction.

Missed Dose and Timing

If you miss a weekly dose, the safest approach is to follow your clinician’s instructions. Many once-weekly injectables allow catch-up dosing if remembered within a certain window, but specifics vary by product. Do not take two doses at once. Try to pick a consistent weekly dosing day and set reminders to stay on track.

Storage and Travel Basics

Keep the product in its original carton when possible, away from light and out of reach of children. Many peptide injectables are stored in the refrigerator before first use and protected from freezing, but you should follow the final label for this medicine if and when it becomes available. If room-temperature storage is permitted after first use, do not exceed the time window listed in the official instructions.

For travel, carry your supplies in hand luggage with a small insulated bag if needed. Bring spare needles, alcohol swabs, and a copy of your prescription. A travel letter from your clinician can help during security screening. Do not leave injection devices in a parked car or expose them to direct heat or freezing temperatures.

Pen Handling and Sharps Disposal

If supplied as a prefilled pen, follow these general steps:

• Wash hands and gather the pen, a new needle, swabs, and a sharps container.
• Inspect the device and solution; do not use if damaged or discolored.
• Attach a new needle and remove the outer and inner caps.
• Prime per instructions until you see a drop at the needle tip.
• Choose an injection site, clean with an alcohol swab, and let dry.
• Insert the needle as directed, press the dose button, and hold for the recommended count.
• Remove the needle and place it immediately in a puncture-resistant sharps container.
• Replace the pen cap and store as directed. Never share pens or needles.

Benefits

This dual-agonist approach aims to combine appetite control with metabolic support in a single weekly injection. The treatment may help reduce energy intake and improve fasting and post-meal glucose. A weekly schedule can reduce the number of injections compared with daily options, which many patients find convenient. If a prefilled pen is available, it can simplify setup and dosing.

Because it remains investigational, individual outcomes, dose steps, and titration plans are not finalized. Your prescriber will consider medical history, current medicines, and goals before recommending a specific therapy.

Side Effects and Safety

• Nausea or vomiting
• Diarrhea or constipation
• Abdominal discomfort
• Decreased appetite
• Headache or dizziness
• Fatigue
• Injection-site redness or itching

Serious risks reported with this class can include pancreatitis, gallbladder issues, dehydration-related kidney problems, and severe allergic reactions. GLP-1 receptor–based therapies carry a boxed warning in some markets regarding thyroid C-cell tumors seen in rodents. People with a personal or family history of medullary thyroid carcinoma or MEN 2 should avoid this class. Low blood sugar can occur when used with insulin or sulfonylureas; your clinician may adjust your broader plan to reduce that risk.

Drug Interactions and Cautions

Using this therapy with insulin or sulfonylureas can increase hypoglycemia risk. Because gastric emptying is slowed, absorption of certain oral medicines can change, especially agents with a narrow therapeutic index. Alcohol may worsen stomach symptoms. Diuretics can increase dehydration risk. Corticosteroids may raise blood sugar and complicate diabetes control. Avoid combining weight-management medicines unless your prescriber specifically recommends it.

What to Expect Over Time

Stomach-related symptoms are commonly reported early in treatment with this class and may lessen with continued use. Weight and glucose changes, when they occur, typically build gradually with steady dosing, nutrition, and activity. Regular follow-up allows your healthcare professional to assess response, adjust your overall plan, and watch for side effects.

Compare With Alternatives

Several approved options may be considered depending on your goals and medical history. For chronic weight management, Zepbound® (tirzepatide) is a dual-incretin therapy with once-weekly dosing. For type 2 diabetes with or without weight goals, Mounjaro® Kwikpen Pre Filled Pen offers a similar weekly schedule. To learn about other pathways and outcomes, see comparative insights in Orforglipron Vs Rybelsus and broader lifestyle guidance in Diet And Weight Loss.

Pricing and Access

Check current pricing on this page and review typical cash-pay savings compared with many US retail options. Start your order to see your estimated total before confirming. Your order will be processed with US delivery from Canada through licensed pharmacies. Secure, encrypted checkout is used. Availability can change based on regulatory status and supply.

Availability and Substitutions

If this item is unavailable or not yet approved for your region, your prescriber may recommend a suitable alternative. Stock and fulfillment vary. We cannot provide restock dates or guarantees, but we will display current availability when you begin your order.

Patient Suitability and Cost-Saving Tips

Candidates are typically adults with obesity or type 2 diabetes who have not reached goals with lifestyle measures alone. It may not be appropriate for certain thyroid conditions, past pancreatitis, severe gastrointestinal disease, or during pregnancy. Share your full medication list to check for potential conflicts.

• Multi-month fills: When feasible, larger quantities can reduce refill frequency and some per-shipment fees.
• Refill reminders: Set calendar alerts to keep weekly dosing on schedule.
• Consistent routine: Choose a dosing day and keep supplies together for easy access.
• Travel-ready pack: Keep backup needles, swabs, and a sharps container or travel-safe alternative.
• Lifestyle support: Pair therapy with nutrition, activity, and sleep routines for better outcomes.

Questions to Ask Your Clinician

• Is this class appropriate for my medical history and current medicines?
• How should weekly injections fit with my meals, activity, and glucose checks?
• What side effects should I watch for, and when should I call the clinic?
• Could this therapy interact with my oral medicines due to delayed stomach emptying?
• If I have nausea, which non-prescription options are acceptable?
• How will we track weight, A1C, and other labs over time?
• What alternatives are reasonable if I cannot tolerate this class?

Authoritative Sources

• Innovent Biologics Pipeline
• ClinicalTrials.gov: Mazdutide
• Health Canada Drug Product Database

Ready to proceed? Start an order now for prompt, express, cold-chain shipping. Ships from Canada to US.

This information is educational and not a substitute for professional medical advice. Always follow your prescriber’s instructions.